
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A
**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934**
(Amendment No.)

Filed by the Registrant Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under § 240.14a-12

Cue Biopharma, Inc.
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required
 - Fee paid previously with preliminary materials
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-
-



P.O. BOX 3818, CARY, NC 27512-9603

Cue Biopharma, Inc.
Important Notice Regarding the Availability
of Proxy Materials

Stockholders Meeting to be held on
June 7, 2023


For Stockholders of record on April 12, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting online, go to: www.proxydocs.com/CUE

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



For a convenient way to view proxy materials and VOTE go to
www.proxydocs.com/CUE

Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 26, 2023.

To order paper materials, use one of the following methods.



INTERNET
www.investorelections.com/CUE

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.



TELEPHONE
(866) 648-8133



*** E-MAIL**
paper@investorelections.com

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

Cue Biopharma, Inc.

Proxy Materials Available to View or Receive: Proxy Statement & Annual Report

Meeting Type: Annual Meeting of Stockholders

Date: Wednesday, June 7, 2023

Time: 9:00 AM, Eastern Time

Place: Annual Meeting to be held live via the internet - please visit www.proxydocs.com/CUE for more details.

You must pre-register to attend the meeting online and/or participate at www.proxydocs.com/CUE.

SEE REVERSE FOR FULL AGENDA

Cue Biopharma, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR EACH NOMINEE IN PROPOSAL 1, FOR PROPOSAL 2, AND FOR PROPOSAL 3

THE BOARD RECOMMENDS THAT AN ADVISORY VOTE ON THE COMPENSATION FOR NAMED EXECUTIVE OFFICERS BE HELD EVERY 1 YEAR.

PROPOSAL

1. Election of seven directors to our board of directors, each to serve until the 2024 annual meeting of stockholders
 - 1.01 Daniel R. Passeri
 - 1.02 Frank Morich
 - 1.03 Frederick Driscoll
 - 1.04 Aaron Fletcher
 - 1.05 Peter Klener
 - 1.06 Patrick Verheyen
 - 1.07 Pamela Garzone
2. The ratification of the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3. The approval, on a non-binding advisory basis, of the compensation of our named executive officers.
4. The recommendation, on a non-binding advisory basis, of the frequency of future advisory votes on the compensation of our named executive officers.

NOTE: The proxies are authorized to vote, in their discretion, upon such other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.